Clovis Oncology’s Rociletinib (CO-1686) Phase 2 Study Results at ASCO 2015
May 31, 2015Clovis Oncology’s Rociletinib (CO-1686) Phase 2 study results demonstrate consistent and promising clinical activity and disease control in very advanced patients with EGFR-mutant non-small cell lung cancer (NSCLC).
More »
In New Cardiac Surgery Study NephroCheck® Kidney Biomarkers Rise To The Occasion
May 29, 2015Astute Medical's NephroCheck® Test was used in study published in the Journal of the American Medical Association to confirm that post-operative elevations of two kidney biomarkers act as an alarm for risk of AKI.
More »
Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity
May 29, 2015Epic Sciences presented single cell sequencing data from metastatic castrate resistant prostate cancer patients at 2015 ASCO. The study revealed that late stage patients have heterogeneous clonal CTC populations harboring separate genetic alterations.
More »